-
Scientific Reports Jun 2024The development of nanomaterials has been speedily established in recent years, yet nanoparticles synthesized by traditional methods suffer unacceptable toxicity and the...
The development of nanomaterials has been speedily established in recent years, yet nanoparticles synthesized by traditional methods suffer unacceptable toxicity and the sustainability of the procedure for synthesizing such nanoparticles is inadequate. Consequently, green biosynthesis, which employs biopolymers, is gaining attraction as an environmentally sound alternative to less sustainable approaches. Chitosan-encapsulated nanoparticles exhibit exceptional antibacterial properties, offering a wide range of uses. Chitosan, obtained from shrimp shells, aided in the environmentally friendly synthesis of high-purity zinc oxide nanoparticles (ZnO NPs) with desirable features such as the extraction yield (41%), the deacetylation (88%), and the crystallinity index (74.54%). The particle size of ZnO NPs was 12 nm, while that of chitosan-ZnO NPs was 21 nm, and the bandgap energies of these nanomaterials were 3.98 and 3.48, respectively. The strong antibacterial action was demonstrated by ZnO NPs, chitosan-ZnO NPs, and chitosan-ZnO/PVP, particularly against Gram-positive bacteria, making them appropriate for therapeutic use. The photocatalytic degradation abilities were also assessed for all nanoparticles. At a concentration of 6 × 10 M, chitosan removed 90.5% of the methylene blue (MB) dye, ZnO NPs removed 97.4%, chitosan-coated ZnO NPs removed 99.6%, while chitosan-ZnO/PVP removed 100%. In the case of toluidine blue (TB), at a concentration of 4 × 10 M, the respective efficiencies were 96.8%, 96.8%, 99.5%, and 100%, respectively. Evaluation of radical scavenger activity revealed increased scavenging of ABTS and DPPH radicals by chitosan-ZnO/PVP compared to individual zinc oxide or chitosan-ZnO, where the IC50 results were 0.059, 0.092, 0.079 mg/mL, respectively, in the ABTS test, and 0.095, 0.083, 0.061, and 0.064 mg/mL in the DPPH test, respectively. Moreover, in silico toxicity studies were conducted to predict the organ-specific toxicity through ProTox II software. The obtained results suggest the probable safety and the absence of organ-specific toxicity with all the tested samples.
Topics: Chitosan; Zinc Oxide; Anti-Bacterial Agents; Catalysis; Nanoparticles; Microbial Sensitivity Tests; Metal Nanoparticles; Biphenyl Compounds; Green Chemistry Technology
PubMed: 38926522
DOI: 10.1038/s41598-024-65579-z -
BMJ (Clinical Research Ed.) Jun 2024
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors
PubMed: 38925802
DOI: 10.1136/bmj.q1424 -
Arteriosclerosis, Thrombosis, and... Jul 2024
Topics: Proprotein Convertase 9; Humans; Cellular Senescence; Apoptosis; Cardiovascular Diseases; Animals; PCSK9 Inhibitors; Signal Transduction
PubMed: 38924434
DOI: 10.1161/ATVBAHA.124.320140 -
Toxins May 2024The aim of this study was to investigate the effects of aflatoxin B (AFB) on cholestasis in duck liver and its nutritional regulation. Three hundred sixty 1-day-old...
The aim of this study was to investigate the effects of aflatoxin B (AFB) on cholestasis in duck liver and its nutritional regulation. Three hundred sixty 1-day-old ducks were randomly divided into six groups and fed for 4 weeks. The control group was fed a basic diet, while the experimental group diet contained 90 μg/kg of AFB. Cholestyramine, atorvastatin calcium, taurine, and emodin were added to the diets of four experimental groups. The results show that in the AFB group, the growth properties, total bile acid (TBA) serum levels and total superoxide dismutase (T-SOD), glutathione peroxidase (GSH-Px), and glutathione (GSH) liver levels decreased, while the malondialdehyde (MDA) and TBA liver levels increased ( < 0.05). Moreover, AFB caused cholestasis. Cholestyramine, atorvastatin calcium, taurine, and emodin could reduce the TBA serum and liver levels ( < 0.05), alleviating the symptoms of cholestasis. The qPCR results show that AFB upregulated () and () gene expression and downregulated () gene expression in the liver, and taurine and emodin downregulated and gene expression ( < 0.05). In summary, AFB negatively affects health and alters the expression of genes related to liver bile acid metabolism, leading to cholestasis. Cholestyramine, atorvastatin calcium, taurine, and emodin can alleviate AFB-induced cholestasis.
Topics: Animals; Aflatoxin B1; Ducks; Cholestasis; Liver; Bile Acids and Salts; Poultry Diseases; Cholestyramine Resin; Animal Feed
PubMed: 38922135
DOI: 10.3390/toxins16060239 -
Marine Drugs Jun 2024To promote the bioconversion of marine chitin waste into value-added products, we expressed a novel pH-stable -derived chitinase, Chi1, in and subsequently purified,...
To promote the bioconversion of marine chitin waste into value-added products, we expressed a novel pH-stable -derived chitinase, Chi1, in and subsequently purified, characterized, and evaluated it for its chitin-converting capacity. Our results indicated that Chi1 is of the glycoside hydrolase (GH) family 18 with a molecular weight of approximately 57 kDa, consisting of a GH18 catalytic domain and a cellulose-binding domain. We recorded its optimal activity at pH 5.0 and 55 °C. It exhibited excellent stability in a wide pH range of 3.0-10.0. Mg (5 mM), and dithiothreitol (10 mM) significantly promoted Chi1 activity. Chi1 exhibited broad substrate specificity and hydrolyzed chitin, chitosan, cellulose, soluble starch, and -acetyl chitooligosaccharides with polymerization degrees ranging from three to six. Moreover, Chi1 exhibited an endo-type cleavage pattern, and it could efficiently convert colloidal chitin into -acetyl-D-glucosamine (GlcNAc) and (GlcNAc) with yields of 227.2 and 505.9 mg/g chitin, respectively. Its high chitin-degrading capacity and exceptional pH tolerance makes it a promising tool with potential applications in chitin waste treatment and bioactive oligosaccharide production.
Topics: Chitinases; Chitin; Hydrogen-Ion Concentration; Substrate Specificity; Micromonospora; Hydrolysis; Escherichia coli; Chitosan; Enzyme Stability
PubMed: 38921598
DOI: 10.3390/md22060287 -
Biosensors Jun 2024Nowadays, biosensors are gaining increasing interest in foods' and beverages' quality control, owing to their economic production, enhanced sensitivity, specificity, and...
Nowadays, biosensors are gaining increasing interest in foods' and beverages' quality control, owing to their economic production, enhanced sensitivity, specificity, and faster analysis. In particular, colorimetric biosensors can be combined with color recognition applications on smartphones for the detection of analytes, rendering the whole procedure more applicable in everyday life. Herein, chitosan (CS) films were prepared with the deep eutectic solvent (DES) choline chloride/urea/glycerol (ChCl:U:Gly). Glucose oxidase (GOx), a widely utilized enzyme in quality control, was immobilized within CS films through glutaraldehyde (GA), leading to the formation of CS/GOx films. The optimized GOx concentration and DES content were determined for the films. Moreover, the effect of the pH and temperature of the glucose oxidation reaction on the enzymatic activity of GOx was studied. The structure, stability, and specificity of the CS/GOx films as well as the Km values of free and immobilized GOx were also determined. Finally, the analytical performance of the films was studied by using both a spectrophotometer and a color recognition application on a smartphone. The results demonstrated that the films were highly accurate, specific to glucose, and stable when stored at 4 °C for 4 weeks and when reused 10 times, without evident activity loss. Furthermore, the films displayed a good linear response range (0.1-0.8 mM) and a good limit of detection (LOD, 33 μM), thus being appropriate for the estimation of glucose concentration in real samples through a smartphone application.
Topics: Biosensing Techniques; Chitosan; Smartphone; Colorimetry; Glucose; Beverages; Glucose Oxidase; Enzymes, Immobilized
PubMed: 38920603
DOI: 10.3390/bios14060299 -
Biosensors May 2024Glucosamine-chitosan synthesized by the Maillard reaction was combined with montmorillonite to obtain a nanohybrid composite to immobilize horseradish peroxidase. The...
Glucosamine-chitosan synthesized by the Maillard reaction was combined with montmorillonite to obtain a nanohybrid composite to immobilize horseradish peroxidase. The material combines the advantageous properties of clay with those of the chitosan derivative; has improved water solubility and reduced molecular weight and viscosity; involves an eco-friendly synthesis; and exhibits ion exchange capacity, good adhesiveness, and a large specific surface area for enzyme adsorption. The physicochemical characteristics of the composite were analyzed by infrared spectroscopy and X-ray diffraction to determine clay-polycation interactions. The electrochemical response of the different polyphenols to glassy carbon electrodes modified with the composite was evaluated by cyclic voltammetry. The sensitivity and detection limit values obtained with the biosensor toward hydroquinone, chlorogenic acid, catechol, and resorcinol are (1.6 ± 0.2) × 10 µA mM and (74 ± 8) nM; (1.2 ± 0.1) × 10 µA mM and (26 ± 3) nM; (16 ± 2) µA mM and (0.74 ± 0.09) μM; and (3.7± 0.3) µA mM and (3.3 ± 0.2) μM, respectively. The biosensor was applied to quantify polyphenols in pennyroyal and lemon verbena extracts.
Topics: Bentonite; Biosensing Techniques; Polyphenols; Chitosan; Horseradish Peroxidase; Enzymes, Immobilized; Electrochemical Techniques; Glucosamine; Electrodes
PubMed: 38920582
DOI: 10.3390/bios14060278 -
Acta Chimica Slovenica Jun 2024Diabetes mellitus is a chronic metabolic disorder marked by elevated blood sugar levels, leading to organ dysfunction. Curcumin, derived from turmeric, exhibits promise...
Diabetes mellitus is a chronic metabolic disorder marked by elevated blood sugar levels, leading to organ dysfunction. Curcumin, derived from turmeric, exhibits promise in managing type II diabetes. Nanomicelles were created by conjugating curcumin with chitosan through succinic anhydride. Succinyl-curcumin, the resultant compound, was esterified with chitosan to form a polymer prodrug conjugate. Nanomicelles, formed via dialysis, were spherical with a hydrodynamic size of 49.37 nm. In vitro release studies revealed 97% curcumin release at pH 5 in 7 days. A 21-day experiment on diabetic mice compared nanomicelles, standard drug, and free curcumin's impact on fasting blood glucose. The study showcased gradual, controlled curcumin release from nanomicelles, suggesting their potential in type II diabetes treatment.
Topics: Animals; Curcumin; Chitosan; Diabetes Mellitus, Type 2; Micelles; Mice; Mice, Inbred BALB C; Diabetes Mellitus, Experimental; Prodrugs; Nanoparticles; Male; Blood Glucose; Hypoglycemic Agents
PubMed: 38919100
DOI: 10.17344/acsi.2024.8658 -
Journal of Cardiothoracic Surgery Jun 2024We previously demonstrated that the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) play an important role in the regulation of alloimmune responses....
Graft protective effects and donor-specific antibody suppression by CD4CD25Foxp3 regulatory T cell induced by HMG-CoA reductase inhibitor rosuvastatin in a murine heart transplant model.
BACKGROUND
We previously demonstrated that the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) play an important role in the regulation of alloimmune responses. However, little is known regarding the effects of statin on allograft protection or donor-specific antibodies (DSA). In this study, we investigated the graft-protective and immunomodulatory effects of rosuvastatin in a model of fully major histocompatibility complex-mismatched murine cardiac allograft transplantation.
METHODS
CBA mice underwent transplantation of C57BL/6 (B6) hearts and received 50 and 500 μg/kg/day of rosuvastatin from the day of transplantation until seven days after the completion of transplantation. To confirm the requirement for regulatory T cells (Tregs), we administered an anti-interleukin-2 receptor alpha antibody (PC-61) to rosuvastatin-treated CBA recipients. Additionally, histological and fluorescent staining, cell proliferation analysis, flow cytometry, and DSA measurements were performed.
RESULTS
CBA recipients with no treatment rejected B6 cardiac graft acutely (median survival time [MST], 7 days). CBA mice treated with 500 μg/kg/day of rosuvastatin prolonged allograft survival (MSTs, 77 days). Fluorescent staining studies showed that rosuvastatin-treated recipients had strong aggregation of CD4Foxp3 cells in the myocardium and around the coronary arteries of cardiac allografts two weeks after grafting. Flow cytometry studies performed two weeks after transplantation showed an increased number of splenic CD4CD25Foxp3 T cells in rosuvastatin-treated recipients. The addition of rosuvastatin to mixed leukocyte cultures suppressed cell proliferation by increasing the number of CD4CD25Foxp3 Tregs. Additionally, Tregs suppressed DSA production in rosuvastatin-treated recipients.
CONCLUSION
Rosuvastatin treatment may be a complementary graft-protective strategy for suppressing DSA production in the acute phase, driven by the promotion of splenic and graft-infiltrating CD4CD25Foxp3 Tregs.
Topics: Animals; Rosuvastatin Calcium; Heart Transplantation; T-Lymphocytes, Regulatory; Mice; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice, Inbred C57BL; Mice, Inbred CBA; Graft Rejection; Graft Survival; Interleukin-2 Receptor alpha Subunit; Male; Forkhead Transcription Factors; Disease Models, Animal; Flow Cytometry
PubMed: 38918849
DOI: 10.1186/s13019-024-02888-4 -
Scientific Reports Jun 2024Contemporary treatment of vitiligo remains a great challenge to practitioners. The vast majority of currently conducted clinical trials of modern therapeutic methods are... (Randomized Controlled Trial)
Randomized Controlled Trial
Contemporary treatment of vitiligo remains a great challenge to practitioners. The vast majority of currently conducted clinical trials of modern therapeutic methods are focused on systemic medications, while there is only a very limited number of reports on new topical treatment in vitiligo. With their pleiotropic activities statins turned out to be efficient in the treatment of various autoimmune/autoinflammatory disorders. The randomized, double-blind placebo-controlled study of topical administration of the active forms of simvastatin and atorvastatin has been designed to evaluate their efficacy in patients with vitiligo. The study was registered in clinicaltrials.gov (registration number NCT03247400, date of registration: 11th August 2017). A total of 24 patients with the active form of non-segmental vitiligo were enrolled in the study. The change of absolute area of skin lesions, body surface area and vitiligo area scoring index were evaluated throughout the 12 week application of ointments containing simvastatin and atorvastatin. Measurements were performed with planimetry and processed using digital software. Use of active forms of simvastatin and atorvastatin did not result in a significant repigmentation of the skin lesions throughout the study period. Within the limbs treated with topical simvastatin, inhibition of disease progression was significantly more frequent than in the case of placebo (p = 0.004), while the difference was not statistically significant for atorvastatin (p = 0.082). Further studies of topical simvastatin in vitiligo patients should be considered.
Topics: Humans; Vitiligo; Atorvastatin; Simvastatin; Male; Female; Double-Blind Method; Adult; Pilot Projects; Middle Aged; Administration, Topical; Young Adult; Treatment Outcome; Adolescent
PubMed: 38918590
DOI: 10.1038/s41598-024-65722-w